{"prompt": "System: \nMake reference to the context given to assess the scenario. If you do not know the answer. just say that \"I don't know\", don't try to make up an answer.\nYou are a physician assistant giving advice on treatment for moderate to severe ulcerative colitis (UC).\n\nANALYSE the given patient profile based on given query based on one of the following criteria:\n- Whether treated patient is new patient or patient under maintenance\n- Prior response to Infliximab\n- Prior failure to Anti-TNF agents\n- Prior failure to Vedolizumab\n- Age\n- Pregnancy\n- Extraintestinale manifestations\n- Pouchitis\n\nFINALLY RETURN up to 2 TOP choices of biological drugs given patient profile. Explain the PROS and CONS of the 2 choices.\nOutput your answer as a list of JSON objects with keys: drug_name, advantages, disadvantages.\n\nsummaries\n\n\nHuman: question", "test_cases": [{"question": "40 year old male with newly diagnosed moderate UC and articular extraintestinal manifestations\n", "answer": "Based on the patient's profile, the top two choices of biological drugs would be Vedolizumab and Infliximab. \n\n1. Vedolizumab:\n   - Advantages: Vedolizumab is gut-selective, which means it specifically targets the gut and can be effective in treating moderate to severe UC. It has been shown to be effective in inducing and maintaining remission in UC patients.\n   - Disadvantages: As Vedolizumab is gut-selective, it may not be as effective in managing extraintestinal manifestations such as articular symptoms. There may also be an increased risk of infection due to its immunosuppressive nature.\n\n2. Infliximab:\n   - Advantages: Infliximab has been shown to be effective in treating both UC and extraintestinal manifestations. It can induce and maintain remission in UC patients and can also manage articular symptoms.\n   - Disadvantages: Infliximab can have side effects including increased risk of infection and potential for allergic reactions. Some patients may also develop antibodies to Infliximab, reducing its effectiveness over time.\n\nPlease note that the choice of treatment should be individualized based on the patient's overall health, lifestyle, and personal preferences, in consultation with their healthcare provider.\n\n[{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Gut-selective, effective in treating moderate to severe UC\", \"disadvantages\": \"May not be as effective in managing extraintestinal manifestations, increased risk of infection\"}, {\"drug_name\": \"Infliximab\", \"advantages\": \"Effective in treating both UC and extraintestinal manifestations\", \"disadvantages\": \"Potential side effects including increased risk of infection and allergic reactions, potential for developing antibodies\"}]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "therapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into\nConsideration\nEIMs are common in IBD, estimated to affect 30%\u201340% of\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\nbefore IBD in one-quarter of the patients113; collaboration\nacross specialties, including but not limited to rheumatolo-\ngists, dermatologists, ophthalmologists, is vital not only to\nprompt referral of patients with EIM suspicious for IBD to\nallow for expedient initiation of therapy for both conditions,\nbut also to allow for consideration of both in the selection of\ntherapy, dose, and chronicity of treatment. For example, VDZ,\nwhich is gut-selective, is associated with an increased risk of"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 4, "text": "tant variables to consider. For the purpose of this discus-\nsion, we risk-stratify patients into mild, moderate, or severe\ndisease\nbased\non\nguidance\nlaid\nout\nby\nthe\nAGA\n(Figure 2)60,64 and illustrate therapeutic options for CD and\nUC in Figures 3 and 4, respectively.\nJuly 2021\nManagement of early IBD\n51\nREVIEWS AND\nPERSPECTIVES"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "", "filename": "otad009.pdf", "page": 14, "text": "extent that they can be indirectly assessed with NMA, are \ngenerally consistent. As with any indirect comparison, the \nresults presented in the present study should be interpreted \nwith caution and in the context of a patient\u2019s individual \nneeds. However, given the limited evidence from head-to-\nhead trials, these results can help clinicians better under-\nstand the growing repertoire of advanced treatments for \nmoderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "Disease Phenotype and Clinical Characteristics\nThe International Organization for the Study of In\ufb02am-\nmatory Bowel Disease and the American Gastroenterological\nAssociation (AGA) provide a framework for categorization of\nCD and UC severity into mild-, moderate-, and high-risk\ngroups based on phenotype and other characteristics.59,60\nIn CD, the presence of large or deep mucosal lesions on\nendoscopy or magnetic resonance imaging (MRI), history of\na \ufb01stula, abscess, or intestinal resection are predictors of\nworse outcomes.59,60 In a prospective population-based\ninception cohort of 213 patients with CD, penetrating\nbehavior was associated with a higher risk of progression to\nperianal disease (HR, 5.65; 95% CI, 2.65\u201312.03) and was a\nrisk factor for resection (HR, 3.92; 95% CI, 1.86\u20138.67) and\nhospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "upadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}]}, {"question": "70 year old female with newly diagnosed severe UC\n", "answer": "Based on the patient's profile, she is a new patient with severe ulcerative colitis (UC) and is of an older age. Considering her age and severity of the disease, the top two choices of biological drugs could be Infliximab and Vedolizumab.\n\n1. Infliximab:\n   - Advantages: Infliximab has been shown to be effective in inducing and maintaining remission in patients with moderate to severe UC. It is also associated with higher rates of mucosal healing and has been ranked highest for all endpoints in all patients.\n   - Disadvantages: Infliximab can have side effects including risk of infections, infusion reactions, and potential for immunogenicity leading to loss of response. It also requires intravenous administration which might not be convenient for all patients.\n\n2. Vedolizumab:\n   - Advantages: Vedolizumab is a gut-selective biologic, which may result in fewer systemic side effects. It has been shown to be effective in inducing and maintaining remission in patients with moderate to severe UC.\n   - Disadvantages: Vedolizumab may take longer to show effects compared to other biologics. It also requires intravenous administration and has potential side effects including risk of infections.\n\nPlease note that the choice of treatment should be individualized based on the patient's overall health, comorbidities, and personal preferences. It is also important to monitor the patient's response to treatment and adjust as necessary.\n\n[{\"drug_name\": \"Infliximab\", \"advantages\": \"Effective in inducing and maintaining remission, associated with higher rates of mucosal healing\", \"disadvantages\": \"Risk of infections, infusion reactions, potential for immunogenicity, requires intravenous administration\"}, {\"drug_name\": \"Vedolizumab\", \"advantages\": \"Gut-selective, may result in fewer systemic side effects, effective in inducing and maintaining remission\", \"disadvantages\": \"May take longer to show effects, requires intravenous administration, potential side effects including risk of infections\"}]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 4, "text": "tant variables to consider. For the purpose of this discus-\nsion, we risk-stratify patients into mild, moderate, or severe\ndisease\nbased\non\nguidance\nlaid\nout\nby\nthe\nAGA\n(Figure 2)60,64 and illustrate therapeutic options for CD and\nUC in Figures 3 and 4, respectively.\nJuly 2021\nManagement of early IBD\n51\nREVIEWS AND\nPERSPECTIVES"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "therapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into\nConsideration\nEIMs are common in IBD, estimated to affect 30%\u201340% of\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\nbefore IBD in one-quarter of the patients113; collaboration\nacross specialties, including but not limited to rheumatolo-\ngists, dermatologists, ophthalmologists, is vital not only to\nprompt referral of patients with EIM suspicious for IBD to\nallow for expedient initiation of therapy for both conditions,\nbut also to allow for consideration of both in the selection of\ntherapy, dose, and chronicity of treatment. For example, VDZ,\nwhich is gut-selective, is associated with an increased risk of"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "nosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-\ntients diagnosed after age 60 years,47 and a meta-analysis\nsuggested\nthat,\nalthough\nelderly\nIBD\npresents\nless\ncommonly with complications, there are similar or higher\nrates of surgery compared to a nonelderly population.48 It is\nbeing increasingly recognized that frailty, rather than\nchronologic age, may be the driver of adverse outcomes in\nthis group.49,50\nOther Demographic Variables\nThere are signi\ufb01cant differences in IBD phenotype\nand outcomes based on race and ethnicity, likely due to\na multitude of factors, both social and biologic. Emer-\ngency department use, hospitalization, complicated dis-\nease\ncourse,\nand\nIBD-related\ndisability\nare\nmore\ncommon in minority and lower socioeconomic status\ngroups.51,52 In a study of 770 patients with IBD, South\nAsian immigrants living in the United Kingdom were\nmore\nlikely\nto"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "more common in female patients (CD: OR, 2.3; 95% CI, 1.9\u2013\n2.8 and UC: OR, 1.5; 95% CI, 1.1\u20132.3, in a large Dutch Bio-\nBank).56 Similarly, in a retrospective pediatric study of\nnearly 1000 patients with CD, girls were more likely to have\nEIMs and less likely to have growth impairment compared\nwith boys,57 the latter is possibly related to lower insulin-\nlike growth factor-1 level in boys.58\nJuly 2021\nManagement of early IBD\n49\nREVIEWS AND\nPERSPECTIVES"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 30, "text": "use of newer small molecules is likely to have greater financial implications. Whether an \ninferior, but cheaper, drug should be used to treat moderate to severe UC is not the subject of \nthe current study. The results of this network meta-analysis could, however, be used to \ninform a cost-effectiveness analysis to help guide future treatment selection.  \nIn summary, this systematic review and network meta-analysis has demonstrated that \nall biological therapies and small molecules, other than adalimumab 160/160mg, adalimumab \n80/40mg, and filgotinib 100mg o.d. were superior to placebo for induction of remission of \nmoderate to severe UC, and all drugs, other than adalimumab 80/40mg, were superior to \nplacebo in terms of endoscopic improvement. Among biological therapies, infliximab ranked \nhighest for all endpoints in all patients, and in patients na\u00efve to anti-TNF-\u03b1 drugs, with \nustekinumab ranked highest for all endpoints in patients exposed to anti-TNF-\u03b1 therapy. In"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\nHepatol 7 (2), 118\u2013127.\nDanese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\nBonovas, S., 2014. Biological agents for moderately to severely active ulcerative\ncolitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n704\u2013711.\nP. Juillerat et al.\nCurrent Research in Pharmacology and Drug Discovery 3 (2022) 100104\n6"}, {"title": "", "filename": "otad009.pdf", "page": 14, "text": "extent that they can be indirectly assessed with NMA, are \ngenerally consistent. As with any indirect comparison, the \nresults presented in the present study should be interpreted \nwith caution and in the context of a patient\u2019s individual \nneeds. However, given the limited evidence from head-to-\nhead trials, these results can help clinicians better under-\nstand the growing repertoire of advanced treatments for \nmoderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding"}]}, {"question": "35 year old male with known moderate UC with prior exposure to infliximab but has worsening colitis on endoscopy despite compliance\n", "answer": "Based on the patient's profile, he has moderate ulcerative colitis and has been previously exposed to infliximab but his condition is worsening. Considering this, the top two choices of biological drugs could be:\n\n1. Ustekinumab: This drug has been ranked highest in patients with prior exposure to TNF antagonists like infliximab for induction of remission and endoscopic improvement in patients with moderate to severe ulcerative colitis.\n\n2. Tofacitinib: This is a small molecule drug that has also been ranked high in patients with prior exposure to TNF antagonists. \n\nHere are the pros and cons of these two choices:\n\nUstekinumab:\n- Advantages: It has been found to be effective in inducing remission and endoscopic improvement in patients who have been previously exposed to TNF antagonists. It is also considered safe with a low risk of serious adverse events.\n- Disadvantages: It requires subcutaneous or intravenous administration which may not be preferred by some patients. \n\nTofacitinib:\n- Advantages: It has been found to be effective in inducing remission and endoscopic improvement in patients who have been previously exposed to TNF antagonists. It is an oral medication which may be more convenient for some patients.\n- Disadvantages: It may have a higher risk of adverse events compared to some other drugs.\n\nHere is the output in JSON format:\n\n[\n  {\n    \"drug_name\": \"Ustekinumab\",\n    \"advantages\": \"Effective in inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists. Low risk of serious adverse events.\",\n    \"disadvantages\": \"Requires subcutaneous or intravenous administration.\"\n  },\n  {\n    \"drug_name\": \"Tofacitinib\",\n    \"advantages\": \"Effective in inducing remission and endoscopic improvement in patients with prior exposure to TNF antagonists. Oral administration.\",\n    \"disadvantages\": \"Higher risk of adverse events compared to some other drugs.\"\n  }\n]", "sources": [{"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "endoscopic improvement. An update to this work from 2020, including data from head-to-\nhead trials of vedolizumab and adalimumab, as well as phase III placebo-controlled trials of \nustekinumab, demonstrated again that infliximab was ranked first for induction of clinical \nremission and endoscopic improvement in biologic-na\u00efve patients, with ustekinumab and \ntofacitinib ranked highest in patients previously exposed to biologics.[23] This later network \nmeta-analysis included 14 induction of remission trials, recruiting almost 5500 patients, \nalthough the Japanese trial of infliximab versus placebo in 208 patients reported by \nKobayashi et al. was not included.[42] In contrast to these previous network meta-analyses, \nour results provide hope that some novel drugs, which are likely to come to market soon, are \npotentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg,"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "What You Need to Know\nBackground\nA systematic review and network meta-analysis is\nneeded to compare ef\ufb01cacy and safety of \ufb01rst-line\n(biologic-na\u00efve) and second-line (prior exposure to\ntumor necrosis factor [TNF] antagonists) agents for\ntreatment of moderate to severely active ulcerative\ncolitis.\nFindings\nIn\ufb02iximab was ranked highest in biologic-na\u00efve pa-\ntients, and ustekinumab and tofacitinib were ranked\nhighest in patients with prior exposure to TNF an-\ntagonists, for induction of remission and endoscopic\nimprovement. More trials of direct comparisons are\nneeded to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "ularly IFX, is an effective option with good safety pro\ufb01le.107\nThiopurines may be considered in moderate UC after\nweighing risks against bene\ufb01ts.64 In patients with severe UC\nrequiring hospitalization, IFX is the preferred biologic for\ninduction and maintenance of remission, with or without\nIMM. Combination therapy in the SUCCESS trial was asso-\nciated with improved clinical, but not endoscopic, outcomes\ncompared to IFX monotherapy.108 When using IFX as a\nmonotherapy in moderate to severe UC, given the potential\nfor the colon to act as a \u201csink\u201d for drugs, we advocate for\nchecking early drug concentrations to ensure proper dosing\nand detecting immunogenicity early along with other\npharmacokinetic and safety-related variables.109 There is no\nclear bene\ufb01t of concomitant mesalamine with biologic\ntherapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7, "text": "patients with moderate\u2013severe ulcerative colitis with\nprior exposure to TNFa antagonists (Figure 2B). With an\nestimated placebo rate of achieving clinical remission of\n3% in included trials, we estimated that 3.2%, 5.6%,\n26.9%, and 26.3% of adalimumab-, vedolizumab-, tofaci-\ntinib-, and ustekinumab-treated patients, respectively,\nwould achieve induction of remission.\nInduction of endoscopic improvement. On direct meta-\nanalysis, tofacitinib and ustekinumab, but not vedolizumab\nor adalimumab, were superior to placebo for induction of\nendoscopic improvement, with minimal heterogeneity\nTable 3. Comparative Ef\ufb01cacy of Pharmacologic Agents for Induction of Clinical Remission and Endoscopic Improvement in\nPatients With Moderate\u2013Severe Ulcerative Colitis With Prior Exposure to Tumor Necrosis Factor-a Antagonists Using\nNetwork Meta-Analysis\nInduction of clinical remission\nInduction of endoscopic\nimprovement\nUstekinumab 6 mg/kg\n0.97 (0.11\u20138.72)\n5.99 (1.13\u201331.76)\n10.71 (2.01\u201357.20)"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "first in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs.  \n\u2022 In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg.  \n\u2022 However, for endoscopic improvement again upadacitinib 45mg o.d. ranked first in \npatients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were anti-\nTNF-\u03b1 na\u00efve.  \n\u2022 None of the drugs studied were more likely to lead to serious adverse events than \nplacebo."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7, "text": "compared. Results of our post-hoc, direct, pairwise meta-\nanalysis for histological remission are shown in the \nappendix (p 28).\nDiscussion \nWe reviewed available efficacy and safety data from RCTs \nof biologics and small molecule drugs (approved or in a \nlate stage of development) for induction and maintenance \ntreatment of patients with moderate-to-severe ulcerative \ncolitis. All small molecule drugs and approved biologics, \nexcept filgotinib 100 mg, were significantly better than \nplacebo in terms of inducing clinical remission and \nendoscopic improvement. A novel finding of this study \nwas that upadacitinib ranked highest for the induction of \nclinical remission and endoscopic improvement, and \nwas notably superior for these outcomes to all other \ninterventions in our network meta-analysis. Infliximab \nranked second for both outcomes. Regarding safety, \nvedolizumab was still ranked as the safest drug in \nterms of adverse events and serious adverse events, as \npreviously \nobserved"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "upadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "therapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into\nConsideration\nEIMs are common in IBD, estimated to affect 30%\u201340% of\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\nbefore IBD in one-quarter of the patients113; collaboration\nacross specialties, including but not limited to rheumatolo-\ngists, dermatologists, ophthalmologists, is vital not only to\nprompt referral of patients with EIM suspicious for IBD to\nallow for expedient initiation of therapy for both conditions,\nbut also to allow for consideration of both in the selection of\ntherapy, dose, and chronicity of treatment. For example, VDZ,\nwhich is gut-selective, is associated with an increased risk of"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}]}, {"question": "60 year old female with newly diagnosed moderate UC with a background of congestive cardiac failure\n", "answer": "Based on the patient's profile, the top two choices of biological drugs could be Vedolizumab and Ustekinumab. \n\nVedolizumab is a gut-selective drug, which means it specifically targets the gut and does not have systemic effects. This could be beneficial for this patient who has a background of congestive cardiac failure. \n\nUstekinumab is another option that could be considered. It is used in patients who have not responded well to or cannot tolerate other medications. It works by blocking a protein that causes inflammation in the body.\n\nHere are the pros and cons of these two drugs:\n\n1. Vedolizumab:\n   - Advantages: It is gut-selective, meaning it specifically targets the gut and does not have systemic effects. This could be beneficial for this patient who has a background of congestive cardiac failure.\n   - Disadvantages: It may not be as effective in patients who have failed anti-TNF therapy. Also, it may not be effective for extraintestinal manifestations of UC.\n\n2. Ustekinumab:\n   - Advantages: It can be used in patients who have not responded well to or cannot tolerate other medications. It is also effective for both the intestinal and extraintestinal manifestations of UC.\n   - Disadvantages: It may have systemic effects, which could potentially impact the patient's congestive cardiac failure. Also, it requires regular monitoring for infections and malignancies.\n\nPlease note that the choice of medication should be individualized based on the patient's overall health, other comorbidities, and personal preferences. The patient should also be closely monitored for any potential side effects of these medications.\n\n[{\"drug_name\": \"Vedolizumab\", \"advantages\": \"Gut-selective, potentially beneficial for patients with congestive cardiac failure\", \"disadvantages\": \"May not be as effective in patients who have failed anti-TNF therapy, may not be effective for extraintestinal manifestations of UC\"}, {\"drug_name\": \"Ustekinumab\", \"advantages\": \"Can be used in patients who have not responded well to or cannot tolerate other medications, effective for both intestinal and extraintestinal manifestations of UC\", \"disadvantages\": \"May have systemic effects, requires regular monitoring for infections and malignancies\"}]", "sources": [{"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "nosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-\ntients diagnosed after age 60 years,47 and a meta-analysis\nsuggested\nthat,\nalthough\nelderly\nIBD\npresents\nless\ncommonly with complications, there are similar or higher\nrates of surgery compared to a nonelderly population.48 It is\nbeing increasingly recognized that frailty, rather than\nchronologic age, may be the driver of adverse outcomes in\nthis group.49,50\nOther Demographic Variables\nThere are signi\ufb01cant differences in IBD phenotype\nand outcomes based on race and ethnicity, likely due to\na multitude of factors, both social and biologic. Emer-\ngency department use, hospitalization, complicated dis-\nease\ncourse,\nand\nIBD-related\ndisability\nare\nmore\ncommon in minority and lower socioeconomic status\ngroups.51,52 In a study of 770 patients with IBD, South\nAsian immigrants living in the United Kingdom were\nmore\nlikely\nto"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "more common in female patients (CD: OR, 2.3; 95% CI, 1.9\u2013\n2.8 and UC: OR, 1.5; 95% CI, 1.1\u20132.3, in a large Dutch Bio-\nBank).56 Similarly, in a retrospective pediatric study of\nnearly 1000 patients with CD, girls were more likely to have\nEIMs and less likely to have growth impairment compared\nwith boys,57 the latter is possibly related to lower insulin-\nlike growth factor-1 level in boys.58\nJuly 2021\nManagement of early IBD\n49\nREVIEWS AND\nPERSPECTIVES"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 4, "text": "tant variables to consider. For the purpose of this discus-\nsion, we risk-stratify patients into mild, moderate, or severe\ndisease\nbased\non\nguidance\nlaid\nout\nby\nthe\nAGA\n(Figure 2)60,64 and illustrate therapeutic options for CD and\nUC in Figures 3 and 4, respectively.\nJuly 2021\nManagement of early IBD\n51\nREVIEWS AND\nPERSPECTIVES"}, {"title": "", "filename": "otad009.pdf", "page": 14, "text": "extent that they can be indirectly assessed with NMA, are \ngenerally consistent. As with any indirect comparison, the \nresults presented in the present study should be interpreted \nwith caution and in the context of a patient\u2019s individual \nneeds. However, given the limited evidence from head-to-\nhead trials, these results can help clinicians better under-\nstand the growing repertoire of advanced treatments for \nmoderately to severely active UC.\nSupplementary Data\nSupplementary data is available at Crohn\u2019s and Colitis 360 \nonline.\nFunding\nThis work was supported by AbbVie Inc., who funded this \nstudy and participated in the study design, research, analy-\nsis, data collection, interpretation of data, reviewing, and ap-\nproval of the publication. All authors had access to relevant \ndata and participated in the drafting, review, and approval of \nthis publication. No honoraria or payments were made for \nauthorship. Medicus Economics LLC has received funding"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "\u2020Medicus Economics LLC, Milton, Massachusetts, USA\n\u2021Cedars-Sinai Medical Center, Los Angeles, California, USA\n\u00a7Department of Gastroenterology & Hepatology, University Hospital Leuven, KU Leuven, Leuven, Belgium\n\u2016Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele, Department of Gastroenterology, University Vita-Salute San Raffaele, Milan, \nItaly\n\u00b6Department of Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan, USA\n#Cytel, Inc., Waltham, Massachusetts, USA\n**AbbVie Inc., North Chicago, Illinois, USA\nAddress correspondence to: Remo Panaccione, MD, FRCPC, Rm 6D32, TRW Building, 3280 Hospitals Drive NW, Calgary, AB T3R1B1, Canada (rpanacci@\nucalgary.ca).\nBackground:  Given rapid innovation in advanced therapies for moderately to severely active ulcerative colitis (UC), we investigated their com-\nparative efficacy and safety during induction and maintenance through network meta-analysis."}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "Disease Phenotype and Clinical Characteristics\nThe International Organization for the Study of In\ufb02am-\nmatory Bowel Disease and the American Gastroenterological\nAssociation (AGA) provide a framework for categorization of\nCD and UC severity into mild-, moderate-, and high-risk\ngroups based on phenotype and other characteristics.59,60\nIn CD, the presence of large or deep mucosal lesions on\nendoscopy or magnetic resonance imaging (MRI), history of\na \ufb01stula, abscess, or intestinal resection are predictors of\nworse outcomes.59,60 In a prospective population-based\ninception cohort of 213 patients with CD, penetrating\nbehavior was associated with a higher risk of progression to\nperianal disease (HR, 5.65; 95% CI, 2.65\u201312.03) and was a\nrisk factor for resection (HR, 3.92; 95% CI, 1.86\u20138.67) and\nhospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1, "text": "months (IQR, 1\u201324 months), respectively. Adults were more\nlikely to present with strictures (P < .001) and require\nbowel surgery (P < .001). Furthermore, the duration of\ndiagnostic delay has been associated with complications\nsuch as strictures and internal \ufb01stulae.25 In a study, of adult\nCD patients in France, delay in diagnosis longer than 13\nmonths was associated with higher risk of a major surgery\n(P \u00bc .05).26\nEvidence of Disease Activity Before Diagnosis\nThere is a signi\ufb01cant increase in gastrointestinal symp-\ntoms before IBD diagnosis (9.6% and 10.4% 5 years before\nCD and UC diagnosis, respectively, compared with 5.8% of\ncontrols).27 In addition, patients who were diagnosed with\nirritable bowel syndrome or depression were less likely to\nreceive timely specialist referral (irritable bowel syndrome:\nhazard ratio [HR], 0.77; 95% con\ufb01dence interval [CI], 0.60\u2013\n0.99, depression: HR, 0.77, 95% CI, 0.60\u20130.98), suggesting\nthat delays in IBD diagnosis may be related to focusing on"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 8, "text": "therapy in UC and it can be stopped in patients escalating to\nbiologics.110 Some patients may present with acute severe\nUC\nwhere\nTNFi,\ncyclosporine,\nor\nsubtotal\ncolectomy\nfollowed by ileal pouch anal anastomosis can be a good\ninitial strategy; discussion of management of acute severe\nUC is beyond the scope of this article.\nTaking Extraintestinal Manifestation Into\nConsideration\nEIMs are common in IBD, estimated to affect 30%\u201340% of\npatients.111,112 In a Swiss cohort study, symptoms of EIMs\nbefore IBD in one-quarter of the patients113; collaboration\nacross specialties, including but not limited to rheumatolo-\ngists, dermatologists, ophthalmologists, is vital not only to\nprompt referral of patients with EIM suspicious for IBD to\nallow for expedient initiation of therapy for both conditions,\nbut also to allow for consideration of both in the selection of\ntherapy, dose, and chronicity of treatment. For example, VDZ,\nwhich is gut-selective, is associated with an increased risk of"}]}, {"question": "38 year old female with newly diagnosed moderate UC and psoriasis\n", "answer": "[\n{\n\"drug_name\": \"Ustekinumab\",\n\"advantages\": \"Ustekinumab is a biological therapy that has shown efficacy in patients with moderate to severe UC. It is particularly beneficial for patients with extraintestinal manifestations such as psoriasis, as it can treat both conditions simultaneously. It is also a good option for patients who are naive to anti-TNF-\u03b1 drugs.\",\n\"disadvantages\": \"As with any medication, there are potential side effects, including increased risk of infections. It may also not be as effective in patients who have previously been exposed to anti-TNF-\u03b1 therapies.\"\n},\n{\n\"drug_name\": \"Vedolizumab\",\n\"advantages\": \"Vedolizumab is another biological therapy that has shown efficacy in treating moderate to severe UC. It is an anti-integrin antibody that specifically targets the gut, potentially leading to fewer systemic side effects.\",\n\"disadvantages\": \"While Vedolizumab has been shown to be effective in treating UC, it may not be as effective in treating psoriasis. Therefore, additional treatment may be needed for the patient's psoriasis. There is also a risk of side effects, including increased risk of infections.\"\n}\n]", "sources": [{"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 29, "text": "potentially more efficacious for moderate to severely active UC than existing licensed \ntherapies. \nOur results confirm that all available drugs, other than adalimumab 160/160mg, \nadalimumab 80/40mg, and filgotinib 100mg o.d. were more efficacious than placebo for the \ntreatment of moderate to severe UC, across all endpoints studied at 6 to 14 weeks. All drugs \nwere safe and well-tolerated, with no significant increase in serious adverse events or adverse \nevents leading to withdrawal over the rates seen in the placebo arms, although the RR of"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 27, "text": "Burr et al. \n \n27 of 45 \nDISCUSSION \nWe conducted a contemporaneous systematic review and network meta-analysis of \nbiological therapies and small molecules for moderate to severely active UC. This has \nincorporated data from 28 RCTs and over 12,500 patients. Overall, in terms of clinical \nremission and clinical response at 6 to 14 weeks, upadacitinib 45mg o.d. ranked first in all \npatients, in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients na\u00efve to these \ndrugs. In terms of endoscopic improvement infliximab 10mg/kg ranked first, followed by \nupadacitinib 45mg o.d., and infliximab 5mg/kg. However, again upadacitinib 45mg o.d. \nranked first in patients previously exposed to anti-TNF-\u03b1 therapies, and in patients who were \nanti-TNF-\u03b1 na\u00efve. In terms of safety, upadacitinib 45mg o.d. ranked last for total number of \nadverse events, and ustekinumab 130mg first. However, none of the drugs studied were more"}, {"title": "", "filename": "otad009.pdf", "page": 1, "text": "2\nEfficacy and Safety of Advanced Therapies\nincidence ranges from 9 to 20 cases per 100 000 per year with \nhigher incidence in North America and Northern Europe.1\nThe advanced therapeutic armamentarium for adults \nwith moderately to severely active UC is rapidly evolving. \nFor over 20 years, biologics targeting specific inflamma-\ntory pathways have been the mainstay, beginning with those \ntargeting tumor necrosis alpha (TNFi; eg, infliximab [INF], \nadalimumab [ADA], and golimumab [GOL]) followed by \nbiologics with other modes of action (eg, vedolizumab [VED] \nand ustekinumab [UST]). However, treatment limitations for \nmoderately to severely active UC remain, including primary \nnonresponse, secondary loss of response, immunogenicity, and \nparenteral administration.2 To overcome these limitations, \nthere has been increasing interest in small molecule drugs \n(SMDs), which can be orally administered and lack immu-\nnogenicity.3 Of particular interest are SMDs that inhibit the"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 4, "text": "semi-systematic review suggest that IBD cutaneous lesions may respond\nto the newer IBD drugs. This is the case for ustekinumab and less\nfrequently for vedolizumab (Phillips et al., 2020; Ben Abdallah et al.,\n2021). Uveitis also appears to respond to anti-TNF agents (Leal et al.,\n2019), whereas no biological agents, despite high expectations for\nvedolizumab, has shown ef\ufb01cacy in primary sclerosing cholangitis\n(Christensen et al., 2018; Lynch et al., 2020).\nFistula development affects up to 50% of CD patients over 20 years of\ndisease course. Half of these patients experience perianal \ufb01stula (Rub-\nbino et al., 2021). After surgical drainage of pelvic sepsis, medical ther-\napy may be undertaken. Best results so far are obtained with anti-TNF\nagents. Among them, only in\ufb02iximab has been evaluated in a large,\ndedicated placebo-randomized trial. Out of 366 patients who received\ninduction with 5 mg/kg in\ufb02iximab at Week 0, 2 and 6, 195 responders"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 30, "text": "use of newer small molecules is likely to have greater financial implications. Whether an \ninferior, but cheaper, drug should be used to treat moderate to severe UC is not the subject of \nthe current study. The results of this network meta-analysis could, however, be used to \ninform a cost-effectiveness analysis to help guide future treatment selection.  \nIn summary, this systematic review and network meta-analysis has demonstrated that \nall biological therapies and small molecules, other than adalimumab 160/160mg, adalimumab \n80/40mg, and filgotinib 100mg o.d. were superior to placebo for induction of remission of \nmoderate to severe UC, and all drugs, other than adalimumab 80/40mg, were superior to \nplacebo in terms of endoscopic improvement. Among biological therapies, infliximab ranked \nhighest for all endpoints in all patients, and in patients na\u00efve to anti-TNF-\u03b1 drugs, with \nustekinumab ranked highest for all endpoints in patients exposed to anti-TNF-\u03b1 therapy. In"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 8, "text": "Burr et al. \n \n8 of 45 \nIn the last 10 years small molecules, which can be administered orally and on a daily \nbasis, have also been evaluated in moderate to severe UC. These include janus kinase \ninhibitors, such as tofacitinib,[20] and the sphingosine-1-phosphate receptor modulator, \nozanimod.[21] The comparative efficacy and safety of all these drugs has been assessed in \nprior network meta-analyses.[22, 23] These demonstrated that infliximab was ranked highest \noverall for efficacy, and ustekinumab and tofacitinib were ranked highest in patients with \nprevious anti-TNF-\u03b1 exposure. However, this is a rapidly moving field, and there are already \nseveral newer drugs that have shown efficacy in phase III clinical trials that were not \nconsidered in these network meta-analyses.[24-26] We have therefore performed an updated \nnetwork meta-analysis to evaluate the efficacy of all biological therapies and small molecules"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Tsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "gReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%.\nhReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 43%; secondary loss of response, 50%; intolerance, 7%.\niReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 50%; secondary loss of response, 35%; intolerance, 7%.\njIncludes patients with prior exposure to TNF antagonist with or without vedolizumab (13%\u201318% had prior exposure to vedolizumab).\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2183"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1, "text": "de\ufb01ciencies, altered eating habits, in\ufb02ammatory cytokines,\nand corticosteroid use. Marked growth impairment at\ndiagnosis, de\ufb01ned as a height z-score < \u20132.5, is a poor\nprognostic sign.31 Furthermore, IBD patients exhibit \u201ccatch\nup\u201d growth beyond the typically expected age for growth\nplate closure (median additional years to reach adult height:\nmale patients with CD, 1.9 years and male patients with UC,\n2.5 years; female patients with CD: 2.6 years and female\npatients with UC, 2.8 years), suggesting that achieving\nremission even after reaching adolescence may allow for\nmaximal growth potential.18\nEarly Management Can Alter Disease Course and\nPrevent Complications\nData have consistently demonstrated that long-term IBD\ncomplications are mitigated by early treatment and remis-\nsion. In the long-term follow-up data from the CALM trial,\npatients with early CD who achieved deep remission,\ncompared to those who did not, had a signi\ufb01cantly lower"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 2, "text": "multicenter retrospective study reported the outcome of patients with\nlate CD who had failed treatment with one anti-TNF agent and either\nvedolizumab or ustekinumab. After 48 weeks on a third line of biologic\ntherapy the remission rate was 30.7% whereas the surgery rate was\n23.5% (Kassouri et al., 2020).\nThere is a mechanistic role for anti-IL 23 agents in TNF refractory IBD\npatients. During anti TNF treatment, in non-responders compared to re-\nsponders, there is upregulation of apoptosis resistant IL23p19, IL23R,\nand IL17 A as demonstrated by studies using immunophenotyping of T\ncells. (Bek et al., 2016; Schmitt et al., 2019). This phenomenon suggests\nthat ustekinumab (as IL-12/IL-23 inhibitor) and other IL-23 inhibitor\nagents may have a mechanistic potential in late CD (Eftychi et al., 2019)\nwhen an expansion of Th1 and Th17 cells (Veny et al., 2010) may have\noccurred.\n3.2. Disease characteristics and patient pro\ufb01le"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}]}, {"question": "25 year old pregnant woman with severe distal ulcerative colitis\n", "answer": "[\n  {\n    \"drug_name\": \"Infliximab\",\n    \"advantages\": \"Infliximab is a TNF-alpha inhibitor that has been shown to be effective in inducing and maintaining remission in patients with moderate to severe ulcerative colitis. It is also considered safe for use during pregnancy, as it has a low risk of causing birth defects or complications.\",\n    \"disadvantages\": \"Potential side effects of infliximab include increased risk of infections, allergic reactions, and potential complications if the patient has heart failure. It also requires intravenous administration, which can be inconvenient for some patients.\"\n  },\n  {\n    \"drug_name\": \"Adalimumab\",\n    \"advantages\": \"Adalimumab is another TNF-alpha inhibitor that can be effective in treating moderate to severe ulcerative colitis. It is administered via subcutaneous injection, which can be done at home. It is also considered safe for use during pregnancy.\",\n    \"disadvantages\": \"Potential side effects of adalimumab include increased risk of infections, allergic reactions, and potential complications if the patient has heart failure. Some patients may also experience discomfort or skin reactions at the injection site.\"\n  }\n]", "sources": [{"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "Disease Phenotype and Clinical Characteristics\nThe International Organization for the Study of In\ufb02am-\nmatory Bowel Disease and the American Gastroenterological\nAssociation (AGA) provide a framework for categorization of\nCD and UC severity into mild-, moderate-, and high-risk\ngroups based on phenotype and other characteristics.59,60\nIn CD, the presence of large or deep mucosal lesions on\nendoscopy or magnetic resonance imaging (MRI), history of\na \ufb01stula, abscess, or intestinal resection are predictors of\nworse outcomes.59,60 In a prospective population-based\ninception cohort of 213 patients with CD, penetrating\nbehavior was associated with a higher risk of progression to\nperianal disease (HR, 5.65; 95% CI, 2.65\u201312.03) and was a\nrisk factor for resection (HR, 3.92; 95% CI, 1.86\u20138.67) and\nhospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "hospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking\nis associated with complications and need for therapy\nescalation.61\nIn CD, the threshold of suspicion should be low for high-\nquality imaging of the pelvis, such as MRI, to rule our\nperianal CD. In a retrospective study of 136 pediatric CD\npatients, presence of anal \ufb01ssures and skin tags, non-White\nrace, and elevated C-reactive protein (CRP) were risk factors\nfor perianal CD.62 In another study of 274 patients in China\nwith recently diagnosed CD, all of whom underwent MRI\npelvis, asymptomatic perianal \ufb01stulas were diagnosed in\n17.5% of patients and colonic location of CD was a risk\nfactor for asymptomatic perianal \ufb01stulas.63\nIn UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Tsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 0, "text": "adherence,\nprevention\nof\ndisability,\nand\nensuring open communication.\nKeywords: In\ufb02ammatory Bowel Disease; Crohn\u2019s Disease; Ul-\ncerative Colitis; Early Diagnosis; Early Therapy; Personalized\nTherapy; Adult; Pediatric.\nI\nn\ufb02ammatory bowel diseases (IBDs), including the\nmain subtypes Crohn\u2019s disease (CD) and ulcerative\ncolitis (UC), are chronic, progressive, immune-mediated\ndiseases of the intestinal tract that have no cure.1,2 IBDs\nare associated with signi\ufb01cant morbidity, disability, and risk\nof complications.3,4 Although they can occur at any age, IBDs\nare most common among adolescents and young adults. In\ndeveloped counties, IBD incidence, although stable at\napproximately 1%, is higher than mortality, leading to\ncompounding prevalence and rising burden of IBDs.5 In\ndeveloping countries, IBD incidence and prevalence are also\non the rise, especially in the last few decades.6 Direct and\nindirect costs of IBD are substantial. Within the United"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 12, "text": "2013;\n145:996\u20131006.\n15. Bouguen G, Levesque BG, Feagan BG, et al. Treat to\ntarget: a proposed new paradigm for the management of\nCrohn\u2019s\ndisease.\nClin\nGastroenterol\nHepatol\n2015;\n13:1042\u20131050.e2.\n16. Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year\nfollow-up\nstudy\nof\nthe\nnatural\nhistory\nof\nperianal\ncrohn\u2019s disease in a danish population-based inception\ncohort. In\ufb02amm Bowel Dis 2019;25:1227\u20131236.\n17. Rutter M, Saunders B, Wilkinson K, et al. Severity of\nin\ufb02ammation is a risk factor for colorectal neoplasia in\nulcerative colitis. Gastroenterology 2004;126:451\u2013459.\n18. Gupta N, Liu C, King E, et al. Continued statural growth\nin older adolescents and young adults with Crohn\u2019s\ndisease and ulcerative colitis beyond the time of ex-\npected growth plate closure. In\ufb02amm Bowel Dis 2020;\n26:1880\u20131889.\n19. Pariente B, Torres J, Burisch J, et al. SA1895 Validation\nof the L\u00e9mman index in Crohn\u2019s disease. Gastroenter-\nology 2020;158:S-469."}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Parkes, M., Vermeire, S., Rioux, J.D., Mans\ufb01eld, J., Silverberg, M.S., Radford-\nSmith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\ncrohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n387 (10014), 156\u2013167.\nColombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\nSchreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\nmaintenance of clinical response and remission in patients with crohn's disease: the\ncharm trial. Gastroenterology 132 (1), 52\u201365.\nConrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric in\ufb02ammatory bowel disease\nwith biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36\u201351.\nCsontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Pal\ufb01, E., Miheller, P., 2016. The\neffect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\nin in\ufb02ammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49\u201356."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "In UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers\nand prior use of biologics.59 Extensive colitis, deep ulcers,\nneed for corticosteroids, hospitalization, Clostridium dif\ufb01cile,\nand cytomegalovirus infection also indicate higher colec-\ntomy risk.64 Of note, disease extension from limited disease\nto\nextensive\nor\npancolitis\nis\nassociated\nwith\nworse\nprognosis.45,65\nIn addition, co-occurrence of other immune-mediated\nin\ufb02ammatory diseases can occur, most commonly with\npsoriasis and asthma, but also, in more rare instances, with\nother gastrointestinal diseases (eg, celiac, nonalcoholic fatty\nliver disease,66 and eosinophilic esophagitis).67,68 Presence\nof a concomitant immune-mediated in\ufb02ammatory disease is\nFigure\n1. In\ufb02ammatory\nbowel disease severity vs\ndisease activity variables.\nASCA, anti-Saccharomyces\ncerevisiae\nantibodies;\nANCA,\nanti-neutrophil\ncytoplasmic\nantibodies;"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 12, "text": "the IBD patients involves a thoughtful, individualized, and\nwell-rounded assessment and treatment plan, taking into\nconsideration feedback from the patient. Personalized IBD\ncare is fast-evolving, and sophisticated prediction models\nincorporating multi-omic platforms are likely to be the\nfuture of IBD therapeutics.\nSupplementary Material\nNote: To access the supplementary material accompanying\nthis article, visit the online version of Gastroenterology at\nwww.gastrojournal.org, and at http://dxdoi.org/10.1053/\nj.gastro.2021.04.063.\nReferences\n1. Torres J, Mehandru S, Colombel JF, et al. Crohn\u2019s dis-\nease. Lancet 2017;389:1741\u20131755.\n2. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis.\nLancet 2017;389:1756\u20131770.\n3. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The\nnatural history of adult Crohn\u2019s disease in population-\nbased cohorts. Am J Gastroenterol 2010;105:289\u2013297.\n4. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 0, "text": "REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY\nAND HEPATOLOGY\nDouglas J. Robertson and Vincent W. Yang, Section Editors\nApproach to the Management of Recently Diagnosed\nIn\ufb02ammatory Bowel Disease Patients: A User\u2019s Guide for Adult\nand Pediatric Gastroenterologists\nManasi Agrawal,1,* Elizabeth A. Spencer,2,* Jean-Frederic Colombel,1 and Ryan C. Ungaro1\n1The Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; and\n2The Division of Pediatric Gastroenterology and Nutrition, Icahn School of Medicine at Mount Sinai, New York, New York\nIn\ufb02ammatory bowel diseases (IBDs), including Crohn\u2019s\ndisease and ulcerative colitis, are chronic, progressive,\nimmune-mediated diseases of adults and children that\nhave no cure. IBD can cause signi\ufb01cant morbidity and lead\nto complications such as strictures, \ufb01stulas, infections, and\ncancer.\nIn\nchildren,\nIBD\ncan\nalso\nresult\nin\ngrowth\nimpairment and pubertal delays. IBD is highly heteroge-"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}]}, {"question": "56 year old man with moderate to severe ulcerative colitis and ankylosing spondylitis\n", "answer": "Based on the patient's profile, the patient is under maintenance for moderate to severe ulcerative colitis and has an extraintestinal manifestation, ankylosing spondylitis. \n\nGiven this, the top two choices of biological drugs would be Infliximab and Adalimumab. \n\nInfliximab is a TNF-alpha inhibitor that has been shown to be effective in treating both ulcerative colitis and ankylosing spondylitis. \n\nAdalimumab is another TNF-alpha inhibitor that is also effective in treating both conditions. \n\nHere are the pros and cons of each:\n\nInfliximab:\n- Advantages: Infliximab can reduce signs and symptoms of both UC and ankylosing spondylitis, and can induce and maintain remission in UC. It can also improve physical function in patients with ankylosing spondylitis.\n- Disadvantages: Infliximab can have side effects including infections (such as tuberculosis), reactivation of hepatitis B, heart failure, and certain types of cancer. It is also given as an intravenous infusion, which can be less convenient for some patients.\n\nAdalimumab:\n- Advantages: Adalimumab can reduce signs and symptoms and induce remission in patients with UC, and can reduce signs and symptoms in patients with ankylosing spondylitis. It is given as a subcutaneous injection, which some patients may find more convenient.\n- Disadvantages: Adalimumab can have side effects including infections (such as tuberculosis), reactivation of hepatitis B, heart failure, and certain types of cancer.\n\nPlease note that the choice of treatment should be individualized based on the patient's specific circumstances and in consultation with their healthcare provider.\n\n[{\"drug_name\": \"Infliximab\", \"advantages\": \"Can reduce signs and symptoms of both UC and ankylosing spondylitis, and can induce and maintain remission in UC. It can also improve physical function in patients with ankylosing spondylitis.\", \"disadvantages\": \"Can have side effects including infections (such as tuberculosis), reactivation of hepatitis B, heart failure, and certain types of cancer. It is also given as an intravenous infusion, which can be less convenient for some patients.\"}, {\"drug_name\": \"Adalimumab\", \"advantages\": \"Can reduce signs and symptoms and induce remission in patients with UC, and can reduce signs and symptoms in patients with ankylosing spondylitis. It is given as a subcutaneous injection, which some patients may find more convenient.\", \"disadvantages\": \"Can have side effects including infections (such as tuberculosis), reactivation of hepatitis B, heart failure, and certain types of cancer.\"}]", "sources": [{"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Tsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "(P A Olivera); Gastroenterology \nand Endoscopy, IRCCS Ospedale \nSan Raffaele and University \nVita-Salute San Raffaele, \nMilano, Italy \n(Prof S Danese MD); INSERM \nNGERE and Department of \nHepatogastroenterology, \nNancy University Hospital, \nLorraine University, \nVandoeuvre-l\u00e9s-Nancy, France \n(Prof L Peyrin-Biroulet MD) \nCorrespondence to: \nProf Laurent Peyrin-Biroulet, \nINSERM NGERE and Department \nof Hepatogastroenterology, \nNancy University Hospital, \nLorraine University, Vandoeuvre-\nl\u00e8s-Nancy F-54511, France \npeyrinbiroulet@gmail.com\nEfficacy and safety of biologics and small molecule drugs for \npatients with moderate-to-severe ulcerative colitis: \na systematic review and network meta-analysis \nJuan S Lasa*, Pablo A Olivera*, Silvio Danese, Laurent Peyrin-Biroulet\nSummary\nBackground There is a growing armamentarium for the treatment of moderate-to-severe ulcerative colitis. We aimed"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 12, "text": "2013;\n145:996\u20131006.\n15. Bouguen G, Levesque BG, Feagan BG, et al. Treat to\ntarget: a proposed new paradigm for the management of\nCrohn\u2019s\ndisease.\nClin\nGastroenterol\nHepatol\n2015;\n13:1042\u20131050.e2.\n16. Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year\nfollow-up\nstudy\nof\nthe\nnatural\nhistory\nof\nperianal\ncrohn\u2019s disease in a danish population-based inception\ncohort. In\ufb02amm Bowel Dis 2019;25:1227\u20131236.\n17. Rutter M, Saunders B, Wilkinson K, et al. Severity of\nin\ufb02ammation is a risk factor for colorectal neoplasia in\nulcerative colitis. Gastroenterology 2004;126:451\u2013459.\n18. Gupta N, Liu C, King E, et al. Continued statural growth\nin older adolescents and young adults with Crohn\u2019s\ndisease and ulcerative colitis beyond the time of ex-\npected growth plate closure. In\ufb02amm Bowel Dis 2020;\n26:1880\u20131889.\n19. Pariente B, Torres J, Burisch J, et al. SA1895 Validation\nof the L\u00e9mman index in Crohn\u2019s disease. Gastroenter-\nology 2020;158:S-469."}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "In UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers\nand prior use of biologics.59 Extensive colitis, deep ulcers,\nneed for corticosteroids, hospitalization, Clostridium dif\ufb01cile,\nand cytomegalovirus infection also indicate higher colec-\ntomy risk.64 Of note, disease extension from limited disease\nto\nextensive\nor\npancolitis\nis\nassociated\nwith\nworse\nprognosis.45,65\nIn addition, co-occurrence of other immune-mediated\nin\ufb02ammatory diseases can occur, most commonly with\npsoriasis and asthma, but also, in more rare instances, with\nother gastrointestinal diseases (eg, celiac, nonalcoholic fatty\nliver disease,66 and eosinophilic esophagitis).67,68 Presence\nof a concomitant immune-mediated in\ufb02ammatory disease is\nFigure\n1. In\ufb02ammatory\nbowel disease severity vs\ndisease activity variables.\nASCA, anti-Saccharomyces\ncerevisiae\nantibodies;\nANCA,\nanti-neutrophil\ncytoplasmic\nantibodies;"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Parkes, M., Vermeire, S., Rioux, J.D., Mans\ufb01eld, J., Silverberg, M.S., Radford-\nSmith, G., McGovern, D.P., Barrett, J.C., Lees, C.W., 2016. Inherited determinants of\ncrohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet\n387 (10014), 156\u2013167.\nColombel, J.F., Sandborn, W.J., Rutgeerts, P., Enns, R., Hanauer, S.B., Panaccione, R.,\nSchreiber, S., Byczkowski, D., Li, J., Kent, J.D., Pollack, P.F., 2007. Adalimumab for\nmaintenance of clinical response and remission in patients with crohn's disease: the\ncharm trial. Gastroenterology 132 (1), 52\u201365.\nConrad, M.A., Kelsen, J.R., 2020. The treatment of pediatric in\ufb02ammatory bowel disease\nwith biologic therapies. Curr. Gastroenterol. Rep. 22 (8), 36\u201351.\nCsontos, A.A., Molnar, A., Piri, Z., Katona, B., Dako, S., Pal\ufb01, E., Miheller, P., 2016. The\neffect of anti-tnfalpha induction therapy on the nutritional status and dietary intake\nin in\ufb02ammatory bowel disease. J Gastrointestin Liver Dis 25 (1), 49\u201356."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 12, "text": "the IBD patients involves a thoughtful, individualized, and\nwell-rounded assessment and treatment plan, taking into\nconsideration feedback from the patient. Personalized IBD\ncare is fast-evolving, and sophisticated prediction models\nincorporating multi-omic platforms are likely to be the\nfuture of IBD therapeutics.\nSupplementary Material\nNote: To access the supplementary material accompanying\nthis article, visit the online version of Gastroenterology at\nwww.gastrojournal.org, and at http://dxdoi.org/10.1053/\nj.gastro.2021.04.063.\nReferences\n1. Torres J, Mehandru S, Colombel JF, et al. Crohn\u2019s dis-\nease. Lancet 2017;389:1741\u20131755.\n2. Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis.\nLancet 2017;389:1756\u20131770.\n3. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The\nnatural history of adult Crohn\u2019s disease in population-\nbased cohorts. Am J Gastroenterol 2010;105:289\u2013297.\n4. Torres J, Billioud V, Sachar DB, et al. Ulcerative colitis as"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "hospitalization (HR, 1.01; 95% CI, 1.00\u20131.01).16 Ileal and\nupper gastrointestinal disease location and extensive dis-\nease are also markers of severe disease.61 Cigarette smoking\nis associated with complications and need for therapy\nescalation.61\nIn CD, the threshold of suspicion should be low for high-\nquality imaging of the pelvis, such as MRI, to rule our\nperianal CD. In a retrospective study of 136 pediatric CD\npatients, presence of anal \ufb01ssures and skin tags, non-White\nrace, and elevated C-reactive protein (CRP) were risk factors\nfor perianal CD.62 In another study of 274 patients in China\nwith recently diagnosed CD, all of whom underwent MRI\npelvis, asymptomatic perianal \ufb01stulas were diagnosed in\n17.5% of patients and colonic location of CD was a risk\nfactor for asymptomatic perianal \ufb01stulas.63\nIn UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers"}]}, {"question": "38 year old man with severe ulcerative colitis and has lost response to vedolizumab\n", "answer": "Based on the patient's profile, the top two choices of biological drugs could be:\n\n1. Ustekinumab\n2. Infliximab\n\nUstekinumab:\n- Advantages: Ustekinumab has been found to be effective in patients with prior exposure to TNF antagonists. It is also ranked highest in patients with prior exposure to TNF antagonists for induction of remission and endoscopic improvement. It has a lower risk of infections compared to other drugs.\n- Disadvantages: The efficacy of ustekinumab in patients who have failed treatment with vedolizumab is not specifically mentioned in the documents. More trials of direct comparisons are needed to inform clinical decision making with greater confidence.\n\nInfliximab:\n- Advantages: Infliximab has been found to be effective in biologic-naive patients, and it might be a good option for this patient who has lost response to vedolizumab. It is also ranked highest in biologic-naive patients for induction of remission and endoscopic improvement.\n- Disadvantages: The efficacy of infliximab in patients who have failed treatment with vedolizumab is not specifically mentioned in the documents. More trials of direct comparisons are needed to inform clinical decision making with greater confidence.\n\nPlease note that the choice of treatment should be individualized based on the patient's specific condition, preferences, and potential side effects of the drugs. The patient should have a detailed discussion with his healthcare provider to decide the best treatment option.\n\n[{\"drug_name\": \"Ustekinumab\", \"advantages\": \"Effective in patients with prior exposure to TNF antagonists, ranked highest in such patients for induction of remission and endoscopic improvement, lower risk of infections\", \"disadvantages\": \"Efficacy in patients who have failed treatment with vedolizumab is not specifically mentioned, more trials of direct comparisons are needed\"}, {\"drug_name\": \"Infliximab\", \"advantages\": \"Effective in biologic-naive patients, ranked highest in such patients for induction of remission and endoscopic improvement\", \"disadvantages\": \"Efficacy in patients who have failed treatment with vedolizumab is not specifically mentioned, more trials of direct comparisons are needed\"}]", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 0, "text": "control with vedolizumab. Other factors are involved in informed shared \ndecision-making \u2014 comorbid conditions, speed of onset of action and \na patient\u2019s values and preferences, such as the mode of administration, \ncost and access. In most jurisdictions, cost considerations upend these \ndiscussions, with a strong preference for using biosimilars for TNF antag-\nonists and conventional immunosuppressive agents like thiopurines \nand methotrexate in resource-limited settings (Fig.\u00a01).\nSimilar to Crohn\u2019s disease, there is a paucity of head-to-head clini-\ncal trials of advanced immunosuppressive therapies in patients with \nmoderate-to-severe ulcerative colitis. Integrating data from the VAR-\nSITY trial comparing vedolizumab versus adalimumab (Supplementary \nTable\u00a01) with data from phase II and III trials of approved therapies, \nnetwork meta-analyses suggest that upadacitinib, infliximab and ved-\nolizumab are probably the most efficacious therapies for induction"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:\nWe searched publication databases through September 30, 2019, for randomized trials of\nadults with moderate to severe ulcerative colitis treated with TNF antagonists, vedolizumab,\ntofacitinib, or ustekinumab, as \ufb01rst-line or second-line agents, compared with placebo or\nanother active agent. Ef\ufb01cacy outcomes were induction and maintenance of remission and\nendoscopic improvement; safety outcomes were serious adverse events and infections. We\nperformed a \ufb01xed-effects network meta-analysis using the frequentist approach, and calculated\nodds ratios (ORs) and 95% CI values. Agents were ranked using surface under the cumulative\nranking (SUCRA) probabilities. Overall quality of evidence was rated using GRADE (Grading of\nRecommendations, Assessment, Development and Evaluation).\nRESULTS:"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 0, "text": "tumor necrosis factor inhibitor; UC, ulcerative colitis; UST, ustekinumab;\nVDZ, vedolizumab.\nMost current article\n\u00a9 2021 by the AGA Institute\n0016-5085/$36.00\nhttps://doi.org/10.1053/j.gastro.2021.04.063\nGastroenterology 2021;161:47\u201365\nREVIEWS AND\nPERSPECTIVES"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 2, "text": "multicenter retrospective study reported the outcome of patients with\nlate CD who had failed treatment with one anti-TNF agent and either\nvedolizumab or ustekinumab. After 48 weeks on a third line of biologic\ntherapy the remission rate was 30.7% whereas the surgery rate was\n23.5% (Kassouri et al., 2020).\nThere is a mechanistic role for anti-IL 23 agents in TNF refractory IBD\npatients. During anti TNF treatment, in non-responders compared to re-\nsponders, there is upregulation of apoptosis resistant IL23p19, IL23R,\nand IL17 A as demonstrated by studies using immunophenotyping of T\ncells. (Bek et al., 2016; Schmitt et al., 2019). This phenomenon suggests\nthat ustekinumab (as IL-12/IL-23 inhibitor) and other IL-23 inhibitor\nagents may have a mechanistic potential in late CD (Eftychi et al., 2019)\nwhen an expansion of Th1 and Th17 cells (Veny et al., 2010) may have\noccurred.\n3.2. Disease characteristics and patient pro\ufb01le"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1, "text": "immunomodulators (severe disease,  \n \n extraintestinal manifestations)\n\u2022 Ustekinumab (for patients with substantial \n comorbidities or  contraindications to TNF  \n antagonists)\nFirst-line therapy\n\u2022 TNF antagonists: infliximab or adalimumab,  \n preferably in combination with   \n \n \n immunomodulators\n\u2022 Risankizumab or ustekinumab (for patients  \n with substantial comorbidities or  \n \n \n contraindications to TNF antagonists)\nFirst-line therapy\n\u2022 Vedolizumab\n\u2022 Ustekinumab\nFirst-line therapy\n\u2022 Risankizumab or ustekinumab\n\u2022 Vedolizumab\nModerate-to-severely active\nulcerative colitis\nModerate-to-severely active\nulcerative colitis\nModerate-to-severely active\nCrohn's disease\nModerate-to-severely active\nCrohn's disease\nSecond-line therapy\n\u2022 Upadacitinib (or tofacitinib) (for patients with  \n prior failure of infliximab)\n\u2022 Infliximab or ustekinumab (for patients with  \n prior exposure to vedolizumab)\n\u2022 Vedolizumab (moderate disease, for patients  \n who discontinued first-line biologic agent"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 4, "text": "PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; q2w, every 2 weeks; q4w, every 4 weeks; q8w, every 8 weeks; TNF, tumor necrosis factor; VDZ, vedolizumab.\naMaintenance therapy with treat straight-through design.\nbMedian (range).\ncReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 0%; secondary loss of response or intolerance, 100%.\ndOnly including patients with initial response to induction therapy who were rerandomized to placebo or active intervention.\neReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 48%; secondary loss of response, 38%; intolerance, 14%.\nfReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 36%; secondary loss of response, 30%; intolerance, 18%.\ngReasons for discontinuation of prior anti-TNF therapy: primary nonresponse, 58%; secondary loss of response, 40%; intolerance, 2%."}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\noutcomes in vedolizumab- and ustekinumab-treated patients with in\ufb02ammatory\nbowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n(8), 1366\u20131376.\nAtreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\ncolonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544\u2013558.\nBek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\nSystematic review: genetic biomarkers associated with anti-tnf treatment response in\nin\ufb02ammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554\u2013567.\nBen-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\nKobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\nChen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 9, "text": "and route of administration. The recent Study to Evaluate\nthe Safety and Ef\ufb01cacy of Two Drug Regimens in Subjects\nWith Moderate to Severe Ulcerative Colitis-UC trial\ncomparing standard- vs high-dose adalimumab in pa-\ntients with moderate\u2013severe ulcerative colitis failed to\nshow the superiority of higher-dose adalimumab, sug-\ngesting that currently approved dosing of adalimumab is\nunlikely to change, and, hence, the comparative ef\ufb01cacy\nresults will remain similar.31 Our \ufb01ndings also support\nthe observation in the recent head-to-head VARSITY trial\nas well as propensity score-matched analyses from the\nVICTORY consortium that vedolizumab is more effective\nthan adalimumab for long-term maintenance of clinical\nremission; over 8 to 12 weeks of induction therapy,\nhowever, no differences were observed between the 2\nagents.6,32 Moreover, we did not observe any differences\nin the ef\ufb01cacy of vedolizumab and in\ufb02iximab in the\nmaintenance\nof\nclinical\nremission\nor\nendoscopic\n2188 Singh et al"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 4, "text": "semi-systematic review suggest that IBD cutaneous lesions may respond\nto the newer IBD drugs. This is the case for ustekinumab and less\nfrequently for vedolizumab (Phillips et al., 2020; Ben Abdallah et al.,\n2021). Uveitis also appears to respond to anti-TNF agents (Leal et al.,\n2019), whereas no biological agents, despite high expectations for\nvedolizumab, has shown ef\ufb01cacy in primary sclerosing cholangitis\n(Christensen et al., 2018; Lynch et al., 2020).\nFistula development affects up to 50% of CD patients over 20 years of\ndisease course. Half of these patients experience perianal \ufb01stula (Rub-\nbino et al., 2021). After surgical drainage of pelvic sepsis, medical ther-\napy may be undertaken. Best results so far are obtained with anti-TNF\nagents. Among them, only in\ufb02iximab has been evaluated in a large,\ndedicated placebo-randomized trial. Out of 366 patients who received\ninduction with 5 mg/kg in\ufb02iximab at Week 0, 2 and 6, 195 responders"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 7, "text": "in induction trials, we estimated that 58.7%, 40.4%,\n42.7%, 51.9%, 46.5%, and 44.4% of in\ufb02iximab-, adali-\nmumab-, golimumab-, vedolizumab-, tofacitinib-, and\nustekinumab-treated patients, respectively, would ach-\nieve induction of endoscopic improvement.\nSecond-line\npharmacotherapy\nfor\nmoderate\u2013severe\nulcerative colitis. Overall, 7 RCTs including 1580 pa-\ntients with moderate\u2013severe ulcerative colitis with prior\nexposure to TNFa antagonists were identi\ufb01ed. These\nincluded subgroup analyses of trials of adalimumab,21\nvedolizumab,24,25\ntofacitinib,26\nand\nustekinumab.7\nThere were no trials of in\ufb02iximab or golimumab in\npatients with prior exposure to TNFa antagonists who\nmet inclusion criteria. In trials of adalimumab, only pa-\ntients with loss of response or intolerance to a prior\nTNFa antagonist were included. In contrast, in trials of\nvedolizumab, 48% to 58% of patients had inadequate\nresponse to a TNFa antagonist, and in trials of usteki-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 11, "text": "tive colitis. Aliment Pharmacol Ther 2018;47:454\u2013465.\n5.\nSingh S, Fumery M, Sandborn WJ, et al. Systematic review with\nnetwork meta-analysis: \ufb01rst- and second-line pharmacotherapy\nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther\n2018;47:162\u2013175.\n6.\nSands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab\nversus adalimumab for moderate-to-severe ulcerative colitis.\nN Engl J Med 2019;381:1215\u20131226.\n7.\nSands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as\ninduction and maintenance therapy for ulcerative colitis. N Engl\nJ Med 2019;381:1201\u20131214.\n8.\nPuhan MA, Schunemann HJ, Murad MH, et al. A GRADE Working\nGroup approach for rating the quality of treatment effect esti-\nmates from network meta-analysis. BMJ 2014;349:g5630.\n9.\nHutton B, Salanti G, Caldwell DM, et al. The PRISMA extension\nstatement for reporting of systematic reviews incorporating\nnetwork meta-analyses of health care interventions: checklist\nand explanations. Ann Intern Med 2015;162:777\u2013784.\n10."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 1, "text": "What You Need to Know\nBackground\nA systematic review and network meta-analysis is\nneeded to compare ef\ufb01cacy and safety of \ufb01rst-line\n(biologic-na\u00efve) and second-line (prior exposure to\ntumor necrosis factor [TNF] antagonists) agents for\ntreatment of moderate to severely active ulcerative\ncolitis.\nFindings\nIn\ufb02iximab was ranked highest in biologic-na\u00efve pa-\ntients, and ustekinumab and tofacitinib were ranked\nhighest in patients with prior exposure to TNF an-\ntagonists, for induction of remission and endoscopic\nimprovement. More trials of direct comparisons are\nneeded to inform clinical decision-making with\ngreater con\ufb01dence.\nImplications for patient care\nPatients with moderate to severely active ulcerative\ncolitis should receive in\ufb02iximab or vedolizumab as\n\ufb01rst-line therapy, or ustekinumab or tofacitinib if\nthey have prior exposure to TNF antagonists.\n2180 Singh et al\nClinical Gastroenterology and Hepatology Vol. 18, No. 10"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "vs adalimumab: OR, 11.05; 95% CI, 1.79\u201368.41; moderate CE). Vedolizumab had the lowest risk\nof infections (SUCRA, 0.81), followed by ustekinumab (SUCRA, 0.63) in maintenance trials.\nCONCLUSIONS:\nIn a systematic review and network meta-analysis, we found in\ufb02iximab to be ranked highest in\nbiologic-na\u00efve patients, and ustekinumab and tofacitinib were ranked highest in patients with\nprior exposure to TNF antagonists, for induction of remission and endoscopic improvement in\npatients with moderate to severe ulcerative colitis. More trials of direct comparisons are\nneeded to inform clinical decision making with greater con\ufb01dence.\nKeywords: GRADE; Pharmacotherapy; In\ufb02ammatory Bowel Disease; UC; Comparative Ef\ufb01cacy.\nU\nlcerative colitis affects 1 in 200 to 1 in 400 people\nin Western nations, and its global incidence and\nprevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 0, "text": "1998, the regulatory approval of vedolizumab, an anti-\u03b14\u03b27 integrin, \nfollowed in 2014 (barring the approval of natalizumab, an anti-\u03b14 integrin \nfor Crohn\u2019s disease in 2005, which is used infrequently owing to risk of \nprogressive multifocal leukoencephalopathy)1. Since 2014, three more \nclasses of biologic agents and oral small-molecule drugs with unique \nmechanisms of action with varying efficacy and safety profiles have been \napproved for the management of IBD: IL-12 and IL-23 antagonists (IL-12p40 \nand IL-23p40 antagonist, ustekinumab, in 2016; IL-23p19 antagonist, \nrisankizumab, in 2022 \u2014 Crohn\u2019s disease), Janus tyrosine kinase (JAK) \ninhibitors (a pan-JAK inhibitor, tofacitinib in 2019; selective JAK1 inhib-\nitors, upadacitinib and filgotinib in 2022 \u2014 ulcerative colitis) and a sphin-\ngosine 1-phosphate receptor modulator (ozanimod, in 2021 \u2014 ulcerative \ncolitis)2. These advances have brought into focus aspects of comparative"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}]}, {"question": "28 year old woman who has severe extensive ulcerative colitis and has a history of lymphoma which was treated 4 years ago\n", "answer": "I don't know", "sources": [{"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 3, "text": "In UC, corresponding predictors of aggressive disease\nadvised by the International Organization for the Study of\nIn\ufb02ammatory Bowel Disease include active colonic ulcers\nand prior use of biologics.59 Extensive colitis, deep ulcers,\nneed for corticosteroids, hospitalization, Clostridium dif\ufb01cile,\nand cytomegalovirus infection also indicate higher colec-\ntomy risk.64 Of note, disease extension from limited disease\nto\nextensive\nor\npancolitis\nis\nassociated\nwith\nworse\nprognosis.45,65\nIn addition, co-occurrence of other immune-mediated\nin\ufb02ammatory diseases can occur, most commonly with\npsoriasis and asthma, but also, in more rare instances, with\nother gastrointestinal diseases (eg, celiac, nonalcoholic fatty\nliver disease,66 and eosinophilic esophagitis).67,68 Presence\nof a concomitant immune-mediated in\ufb02ammatory disease is\nFigure\n1. In\ufb02ammatory\nbowel disease severity vs\ndisease activity variables.\nASCA, anti-Saccharomyces\ncerevisiae\nantibodies;\nANCA,\nanti-neutrophil\ncytoplasmic\nantibodies;"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Tsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 2, "text": "Articles\nwww.thelancet.com/gastrohep   Vol 7   February 2022 \n163\n\u201csafety\u201d OR \u201cadverse events\u201d]. Additionally, experts in the \nfield were contacted for any unpublished data.\nWe included phase 3 RCTs that met the inclusion criteria: \n(1) studies including adult (\u226518 years) patients with \nmoderate-to-severe ulcerative colitis (defined as a Mayo \nScore of 6\u201312, with an endoscopic sub-score of 2\u20133) who \nwere either biologic-naive or had previously been exposed \nto at least one biologic; (2) studies either evaluating the \nfollowing biologics and small molecule drugs in their \napproved dose regimens, infliximab (intravenous or \nsubcutaneous), adalimumab, golimumab, vedolizumab \n(intravenous or sub cutaneous), ustekinumab (intravenous \nor subcutaneous), tofacitinib, or ozanimod, or studies \nevaluating etroli zumab, upadacitinib, filgotinib, etrasimod, \nor TD-1473; (3) studies including an active comparator or \nplacebo; and (4) studies assessing the following outcomes:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 9, "text": "(infliximab, adalimumab, or golimumab), anti-integrin antibodies (vedolizumab or \netrolizumab), or anti-interleukin-12/23 antibodies (ustekinumab)) or small molecules (janus \nkinase inhibitors (tofacitinib, filgotinib, or upadacitinib) or sphingosine-1-phosphate receptor \nmodulators (ozanimod)) at the doses taken through into testing in phase III clinical trials. \nStudies had to recruit ambulatory adults (\u226518 years) with moderate to severely active UC \n(Supplementary Table 1), and compared biological therapies or small molecules with \nplacebo, or with each other. We required a minimum follow-up duration of 6 weeks.  \nTwo investigators (NEB and ACF) conducted independent literature searches. We \nidentified studies on UC with the terms: inflammatory bowel disease, colitis, or ulcerative \ncolitis (both as medical subject headings and free text terms). We combined these using the \nset operator AND with studies identified with the following terms: infliximab, remicade,"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\nHepatol 7 (2), 118\u2013127.\nDanese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\nBonovas, S., 2014. Biological agents for moderately to severely active ulcerative\ncolitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n704\u2013711.\nP. Juillerat et al.\nCurrent Research in Pharmacology and Drug Discovery 3 (2022) 100104\n6"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "upadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8 \nVermeire S, Danese S, Zhou W, et al. OP23 efficacy and safety of \nupadacitinib as induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from phase 3 \nU-ACCOMPLISH study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S021\u201322.\n9 \nThorlund K, Druyts E, Mills EJ, Fedorak RN, Marshall JK. \nAdalimumab versus infliximab for the treatment of moderate to \nsevere ulcerative colitis in adult patients na\u00efve to anti-TNF therapy: \nan indirect treatment comparison meta-analysis. J Crohn\u2019s Colitis \n2014; 8: 571\u201381.\n10 \nDanese S, Fiorino G, Peyrin-Biroulet L, et al. Biological agents for \nmoderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 7, "text": "TD-1473 were found; results from phase 3 clinical trials \ntesting novel small molecule drugs (eg, etrasimod) in \npatients with moderate-to-severe ulcerative colitis are \nexpected soon, which will warrant further updates \nof this analysis. Additionally, several newer biologics, \nespecially anti-IL-23 drugs (ie, risankizumab, mirikizumab, \nguselkumab, and brazikumab), are also expected to yield \npositive results in phase 3 clinical trials, so these data \nshould also be considered in the future to determine \ntheir position in treatment algorithms. Third, thorough"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\noutcomes in vedolizumab- and ustekinumab-treated patients with in\ufb02ammatory\nbowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n(8), 1366\u20131376.\nAtreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\ncolonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544\u2013558.\nBek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\nSystematic review: genetic biomarkers associated with anti-tnf treatment response in\nin\ufb02ammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554\u2013567.\nBen-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\nKobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\nChen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data"}]}, {"question": "36 year old woman with moderate ulcerative colitis and multiple sclerosis", "answer": "I don't know", "sources": [{"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 7, "text": "Burr et al. \n \n7 of 45 \nINTRODUCTION \n  Ulcerative colitis (UC) is a chronic inflammatory disorder of the bowel that causes \ncontinuous mucosal inflammation commencing in the rectum and extending proximally for a \nvariable extent.[1] It is estimated that UC affects 2.5 million people in Europe,[2] and the \ndisease follows a relapsing and remitting course, with intermittent flares of disease activity, \nsome of which may be moderate to severe. Management of these is medical, for the most \npart, with surgery reserved for patients with refractory disease. Although 5-aminosalicylates \n(5-ASAs) are efficacious for mild to moderate disease activity,[3-6] more severe flares are \nusually treated with corticosteroids.[7] However, these have potentially serious adverse \neffects and a substantial proportion of patients may become either dependent on them to \nmaintain remission,[8] or refractory to them.[9] As a result, over the last 20 years novel"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "published literature, our results might help clinicians to position drugs in treatment algorithms.\nFunding None.\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\nIntroduction \nUlcerative colitis is a chronic, idiopathic, potentially \ndisabling condition that is clinically characterised \nby bloody diarrhoea, abdominal pain, and tenesmus.1 \nUlcerative colitis most commonly presents during the \nthird and fifth decades of life, and is associated with an \nimpaired health-related quality of life and considerable \neconomic burden.2,3\nNearly 20 years ago, the advent of anti-tumour necrosis \nfactor biologics (eg, infliximab, adalimumab, and \ngolimumab) revolutionised therapeutics for ulcerative \ncolitis, enabling better disease control in terms of \nincreasing the rates of mucosal healing, deep remission, \nand corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis,"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "moderately to severely active ulcerative colitis: a systematic review \nand network meta-analysis. Ann Intern Med 2014; 160: 704\u201311.\n11 \nSingh S, Fumery M, Sandborn WJ, Murad MH. Systematic review \nwith network meta-analysis: first- and second-line pharmacotherapy \nfor moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; \n47: 162\u201375.\n12 \nBonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. \nSystematic review with network meta-analysis: comparative \nassessment of tofacitinib and biological therapies for moderate-to-\nsevere ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454\u201365.\n13 \nSingh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and \nsecond-line pharmacotherapies for patients with moderate to \nseverely active ulcerative colitis: an updated network meta-analysis. \nClin Gastroenterol Hepatol 2020; 18: 2179\u201391.e6.\n14 \nMoher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting \nitems for systematic reviews and meta-analyses: the PRISMA"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "prevalence is increasing.1 Although the majority of\npatients have a mild\u2013moderate course, approximately\n10% to 15% of patients experience a severe disease\ncourse with signi\ufb01cant morbidity, with frequent \ufb02ares\nand\nhospitalizations\nrequiring\nimmunosuppressive\ntherapies and corticosteroids, and impose a signi\ufb01cant\ndirect and indirect economic burden in population-\nbased cohorts.2,3 Several treatment options now are\navailable\nfor\nthe\nmanagement\nof\nmoderate\u2013severe\nulcerative colitis, with variable ef\ufb01cacy and safety pro-\n\ufb01les, and positioning different agents in the treatment\ncourse as \ufb01rst-line (in biologic-na\u00efve patients) and\nAbbreviations used in this paper: GRADE, Grading of Recommendations\nAssessment, Development and Evaluation; OCTAVE, Oral Clinical Trials\nfor tofAcitinib in ulceratiVE colitis; OR, odds ratio; RCT, randomized\ncontrolled trial; SUCRA, surface under the cumulative ranking; TNF, tumor\nnecrosis factor.\nMost current article\n\u00a9 2020 by the AGA Institute\n1542-3565/$36.00"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 2, "text": "antagonist\nexposure\nwith\nmoderate\u2013severe ulcerative colitis. The size of the nodes and\nthe thickness of the edges are weighted according to the\nnumber of studies evaluating each treatment and direct\ncomparison, respectively.\nSeptember 2020\nManagement of Moderate\u2013Severe UC 2181"}, {"title": "Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis", "filename": "gutjnl-2021-326390R2 CLEAN.pdf", "page": 5, "text": "Burr et al. \n \n5 of 45 \nSTUDY HIGHLIGHTS \n \nWhat is already known about this subject \n\u2022 Ulcerative colitis (UC) follows a relapsing and remitting course, with intermittent \nflares of disease activity, some of which may be moderate to severe. \n\u2022 These are usually treated with corticosteroids, which have potentially serious adverse \neffects, so biological therapies and small molecules have been developed and licensed \nfor this indication.  \n\u2022 Although previous network meta-analyses have compared their efficacy and safety, \nthis is a rapidly moving field, and there are already several newer drugs that have \nshown efficacy in phase III clinical trials that were not considered in these. \n \nWhat are the new findings \n\u2022 In terms of clinical remission and clinical response, upadacitinib 45mg o.d. ranked \nfirst in all patients, in patients previously exposed to anti-tumour necrosis factor \n(TNF)-\u03b1 therapies, and in patients na\u00efve to these drugs."}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol\nHepatol 7 (2), 118\u2013127.\nDanese, S., Fiorino, G., Peyrin-Biroulet, L., Lucenteforte, E., Virgili, G., Moja, L.,\nBonovas, S., 2014. Biological agents for moderately to severely active ulcerative\ncolitis: a systematic review and network meta-analysis. Ann. Intern. Med. 160 (10),\n704\u2013711.\nP. Juillerat et al.\nCurrent Research in Pharmacology and Drug Discovery 3 (2022) 100104\n6"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 8, "text": "Tsapas A. Systematic review with network meta-analysis: the impact \nof medical interventions for moderate-to-severe ulcerative colitis on \nhealth-related quality of life. Aliment Pharmacol Ther 2018; \n48: 1174\u201385.\n4 \nOlivera P, Danese S, Peyrin-Biroulet L. Next generation of small \nmolecules in inflammatory bowel disease. Gut 2017; 66: 199\u2013209.\n5 \nOlivera P, Danese S, Peyrin-Biroulet L. JAK inhibition in \ninflammatory bowel disease. Expert Rev Clin Immunol 2017; \n13: 693\u2013703.\n6 \nFeagan BG, Danese S, Loftus EV Jr, et al. Filgotinib as induction \nand maintenance therapy for ulcerative colitis (SELECTION): \na phase 2b/3 double-blind, randomised, placebo-controlled trial. \nLancet 2021; 397: 2372\u201384. \n7 \nDanese S, Vermeire S, Zhou W, et al. OP24 efficacy and safety of \nupadacitinib induction therapy in patients with moderately to \nseverely active ulcerative colitis: results from the phase 3 \nU-ACHIEVE study. J Crohn\u2019s Colitis 2021; 15 (suppl 1): S022\u201324.\n8"}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "by bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global \n\u00a9 The Author(s) 2023. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), \nwhich permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.\nReceived for publication: September 21, 2022. Editorial Decision: January 25, 2023\n \nDownloaded from https://academic.oup.com/crohnscolitis360/article/5/2/otad009/7066911 by National University of Singapore user on 23 May 2023"}, {"title": "Positioning therapies for the management of inflammatory bowel disease", "filename": "positioning therapies for IBD mx (Singh S, Nat Rev G&H 2023).pdf", "page": 1, "text": "\u2022 Significant efect on quality of life\nPatients\u2019 values and preferences\n(lifestyle and logistics, speed of onset, costs)\nFig. 1 | Proposed treatment algorithm for patients with moderate-to-severe \nCrohn\u2019s disease and moderate-to-severe ulcerative colitis. The algorithm \nintegrates data on comparative effectiveness and safety of therapies in the \ncontext of an individual patient\u2019s risk of disease-related and treatment-related \ncomplications. TNF, tumour necrosis factor. Adapted with permission from  \nref. 10, Elsevier."}, {"title": "", "filename": "otad009.pdf", "page": 0, "text": "maintenance.\nConclusions:  Upadacitinib may be the most efficacious therapy for moderately to severely active UC based on ITT analyses, with similar safety \nacross advanced therapies.\nLay Summary \nIndirect evidence suggests upadacitinib may be more efficacious than other advanced therapies at achieving clinical response, clinical remis-\nsion, and endoscopic response over 1 year for moderately to severely active ulcerative colitis patients, with similar safety assessments across \nadvanced therapies.\nKey Words: ulcerative colitis, clinical trials, advanced therapies, network meta-analysis\nIntroduction\nUlcerative colitis (UC) is a chronic inflammatory bowel dis-\nease that affects the colorectum and is clinically characterized \nby bloody diarrhea, urgency, tenesmus, abdominal pain, ma-\nlaise, weight loss, and fever. Disease onset commonly occurs \nbetween the ages of 15 and 30 years and the annual global"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "and corticosteroid-free remission, and improving quality \nof life. Biologics with other targets were later approved \nfor the treatment of moderate-to-severe ulcerative colitis, \nnamely vedolizumab and, more recently, usteki numab. \nHowever, \ntreatment \nwith \nbiologics \nhas \nseveral \nlimit ations, including limited efficacy, primary non-\nresponse, secondary loss of response, immunogenicity,"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 2, "text": "Numerous studies suggest that younger age at diagnosis\nis tied to adverse outcomes in both CD and UC.41 In CD,\nbeing diagnosed before the age of 40 years is associated\nwith an increased risk (odds ratio [OR], 2.1; 95% CI, 1.3\u2013\n3.6) of disabling disease 5 years after diagnosis, including\nhigher rates of surgery, hospitalization, steroid dependence,\nand disease recurrence.42,43 In UC, younger age at diagnosis\nis linked to more frequent relapses, colectomy, and colo-\nrectal cancer.44,45 There are con\ufb02icting data on the disease\ncourse in the very-early-onset IBD population of patients\ndiagnosed before age 6 years, with studies reporting both\nsimilar\nand\nworse\noutcomes\nin\nvery-early-onset\nIBD\ncompared to the general pediatric population.46 Similar to\nthe youngest patients with IBD, elderly-onset IBD (diag-\nnosed at 60\u201365 years of age) has con\ufb02icting evidence on\nprognosis, with 1 study reporting fewer hospitalizations and\nless frequent requirement of immunosuppression in pa-"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 0, "text": "SYSTEMATIC REVIEWS AND META-ANALYSES\nSiddharth Singh, Section Editor\nFirst- and Second-Line Pharmacotherapies for Patients With\nModerate to Severely Active Ulcerative Colitis: An Updated\nNetwork Meta-Analysis\nSiddharth Singh,*,\u2021 Mohammad Hassan Murad,\u00a7 Mathurin Fumery,j\nParambir S. Dulai,* and William J. Sandborn*\n*Division of Gastroenterology, \u2021Division of Biomedical Informatics, University of California San Diego, La Jolla, California;\n\u00a7Robert D and Patricia E Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota;\n||Gastroenterology Unit, Peritox UMR I-0I, Amiens University and Hospital, Universit\u00e9 de Picardie Jules Verne, Amiens, France\nBACKGROUND & AIMS:\nWe compared the ef\ufb01cacy and safety of different \ufb01rst-line (biologic-na\u00efve) and second-line\n(prior exposure to tumor necrosis factor [TNF] antagonists) agents for treatment of moder-\nate to severely active ulcerative colitis in a systematic review and network meta-analysis.\nMETHODS:"}, {"title": "First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis", "filename": "PIIS1542356520300446.pdf", "page": 3, "text": "Table 1. Trial and Patient Characteristics in Included Trials of Induction and Maintenance Therapy for Moderate\u2013Severe Ulcerative Colitis\nTrial and intervention\ncharacteristics\nDe\ufb01nition and\ntiming of\noutcome,\nCRem\nMean age, y\n(SD); sex (%\nmale)\nMean disease\nduration (y) (SD);\ndisease extent\n(% extensive\ncolitis)\nConcomitant medications\nMean CRP,\nmg/L (SD)\nPrior anti-\nTNF\ntherapy, %\nImmunomodulators,\n%\nCorticosteroids,\n%\nIn\ufb02iximab\nActive Ulcerative Colitis\nTrials 117a (induction and\nmaintenance therapy)\n62 sites, 2002\u20132005;\nP: 121;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 54\nP: 41 (14); 60\nI: 42 (14); 65\n6.2 (5.9); 45\n5.9 (5.4); 47\n43.8\n54.5\n65.3\n57.9\n17 (27)\n14 (19)\n0\n0\nActive Ulcerative Colitis\nTrials 217a (induction and\nmaintenance therapy)\n55 sites, 2002\u20132005;\nP: 123;\nI: IFX 5 mg/kg, wk 0, 2, 6, then\nq8w\u2013121\nMCS \ufffd2; wk 8,\nwk 30\nP: 39 (14); 58\nI: 41 (13); 63\n6.5 (6.7); 42\n6.7 (5.3); 41\n43.9\n43.0\n48.8\n49.6\n16 (29)\n13 (23)\n0\n0\nJiang et al18a (induction and"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 0, "text": "adherence,\nprevention\nof\ndisability,\nand\nensuring open communication.\nKeywords: In\ufb02ammatory Bowel Disease; Crohn\u2019s Disease; Ul-\ncerative Colitis; Early Diagnosis; Early Therapy; Personalized\nTherapy; Adult; Pediatric.\nI\nn\ufb02ammatory bowel diseases (IBDs), including the\nmain subtypes Crohn\u2019s disease (CD) and ulcerative\ncolitis (UC), are chronic, progressive, immune-mediated\ndiseases of the intestinal tract that have no cure.1,2 IBDs\nare associated with signi\ufb01cant morbidity, disability, and risk\nof complications.3,4 Although they can occur at any age, IBDs\nare most common among adolescents and young adults. In\ndeveloped counties, IBD incidence, although stable at\napproximately 1%, is higher than mortality, leading to\ncompounding prevalence and rising burden of IBDs.5 In\ndeveloping countries, IBD incidence and prevalence are also\non the rise, especially in the last few decades.6 Direct and\nindirect costs of IBD are substantial. Within the United"}, {"title": "Positioning biologics in the treatment of IBD: A practical guide - Which mechanism of action for whom?", "filename": "juillerat 2022.pdf", "page": 5, "text": "Colitis, 2020. Comorbidity, not patient age, is associated with impaired safety\noutcomes in vedolizumab- and ustekinumab-treated patients with in\ufb02ammatory\nbowel disease-a prospective multicentre cohort study. Aliment. Pharmacol. Ther. 52\n(8), 1366\u20131376.\nAtreya, R., Siegmund, B., 2021. Location is important: differentiation between ileal and\ncolonic crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 18 (8), 544\u2013558.\nBek, S., Nielsen, J.V., Bojesen, A.B., Franke, A., Bank, S., Vogel, U., Andersen, V., 2016.\nSystematic review: genetic biomarkers associated with anti-tnf treatment response in\nin\ufb02ammatory bowel diseases. Aliment. Pharmacol. Ther. 44 (6), 554\u2013567.\nBen-Horin, S., Novack, L., Mao, R., Guo, J., Zhao, Y., Sergienko, R., Zhang, J.,\nKobayashi, T., Hibi, T., Chowers, Y., Peyrin-Biroulet, L., Colombel, J.F., Kaplan, G.G.,\nChen, M.H., 2021. Ef\ufb01cacy of biologic drugs in short-duration versus long-duration\nin\ufb02ammatory bowel disease: a systematic review and an individual-patient data"}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 1, "text": "10 years after diagnosis, respectively, and has decreased\nsigni\ufb01cantly during the last 6 decades.14\nThe symptoms associated with IBD can be waxing and\nwaning, but the underlying systemic in\ufb02ammation can lead\nto progressive, cumulative, and often irreversible intestinal\ndamage\nand\nrisk\nof\ncomplications\nif\nnot\ntreated\nadequately.15\nComplications\nassociated\nwith\nongoing\nin\ufb02ammation in CD include strictures, obstructions, \ufb01stulas,\nabscesses, and surgery,3,16 and those associated with UC\ninclude loss of colonic and anorectal function, surgery, and\ncolorectal cancer.2,4,17 Other complications include anemia,\nnutritional de\ufb01ciencies, loss of bone density, and progres-\nsive loss of quality of life. In children, persistent in\ufb02amma-\ntion\nis\nassociated\nwith\ngrowth\nimpairment,\nrisking\npermanent loss of height.18 Similar to other chronic dis-\neases, such as rheumatoid arthritis, the concept of cumula-\ntive damage is now acknowledged in IBD and can be"}, {"title": "Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis", "filename": "1-s2.0-S2468125321003770-main.pdf", "page": 0, "text": "molecule drugs as induction or maintenance therapies for patients with moderate-to-severe ulcerative colitis were \nincluded. Phase 2 RCTs were excluded because of their small sample sizes and inclusion of doses not further explored \nin phase 3 RCTs. Summary data from intention-to-treat analyses were extracted from included reports by JSL and PAO. \nThe primary outcome was the induction of clinical remission. A network meta-analysis was done under the frequentist \nframework, obtaining pairwise odds ratios (ORs) and 95% CIs. The surface under the cumulative ranking (SUCRA) \nwas used to rank the included agents for each outcome. Higher SUCRA scores correlate with better efficacy, whereas \nlower SUCRA scores correlate with better safety. Maintenance data on efficacy for treat-straight-through and \nrandomised responder trials are also presented. This study is registered with PROSPERO, CRD42021225329."}, {"title": "Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A Users Guide for Adult and Pediatric Gastroenterologists", "filename": "agrawal.pdf", "page": 7, "text": "Therapeutic strategies for the management of recentlydiagnosedulcerative colitis. IMMs include thiopurines and methotrexate. 5-ASA, 5-amino salicylic acid; ASUC, acute severe ulcerative colitis; IPAA, ileal pouch anal anastomosis.\n\nRisk stratification: Mild\nClinical features: NA\nTreatment options: 5-ASA (oral and/or topical)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Can consider 5-ASA (with rapid step-up if inadequate response)\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: VDZ or UST\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: Thiopurine\n\nRisk stratification: Moderate\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: TNFi +/- IMM\n\nRisk stratification: Severe\nClinical features: NA\nTreatment options: Subtotal colectomy + IPAA or cyclosporine (for ASUC)\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Psoriasis or psoriatic arthritis\nTreatment options: UST\n\nRisk stratification: Additional consideration: EIM present\nClinical features: Other arthritis\nTreatment options: TNFi\n\n"}]}]}